RGEN — REPLIGEN CORP
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 730272 ·
Last close
$141.01
Market Cap
$7.96B
52W High
$154.00
52W Low
$100.99
ADV30
1,253,797
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 204,128,000 | 110,037,000 | 19,002,000 | 5,008,000 | 2,950,180,000 | 606,783,000 | 838,148,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 197,913,000 | 103,831,000 | 16,348,000 | 13,287,000 | 2,949,699,000 | 566,021,000 | 843,570,000 |
| Sep 2025 | 188,805,000 | 100,515,000 | 12,677,000 | 14,911,000 | 2,923,711,000 | 748,747,000 | 840,624,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$117,417,000
Investing CF
$-298,474,000
Financing CF
$-15,205,000
CapEx
$-25,730,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.90
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$456,248,000
Inventory
$170,458,000
Receivables
$158,587,000
ST Investments
$201,607,000
EBIT TTM
$70,703,000
Pretax Income TTM
$54,440,000
Interest Exp TTM
$16,263,000
Analysts
18
Yahoo Snapshot (yfinance, live)
Total Revenue
$785,100,992
EBITDA
$144,100,992
Free Cash Flow
$113,421,752
Enterprise Value
$7,984,648,192
Total Cash
$810,449,024
Total Debt
$690,942,016
Shares Out
56,435,621
Trailing EPS
$0.73
Book Value
$37.33
ROE
2.0%
ROA
1.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 738,256,000 | 41,560,000 | 48,894,000 | 2,949,699,000 | 843,570,000 | — | 117,417,000 |
| Dec 2024 | 634,439,000 | -31,923,000 | -25,514,000 | 2,829,666,000 | 856,948,000 | — | 175,394,000 |
| Dec 2023 | 632,362,000 | 17,134,000 | 35,596,000 | 2,831,185,000 | 866,340,000 | — | 113,918,000 |
| Dec 2022 | 801,536,000 | 195,941,000 | 185,959,000 | 2,531,600,000 | 620,900,000 | — | 172,083,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.64
Max Pain — expiry 2026-11-20
max pain strike: $135.00 · spot: $141.01 · call oi: 388 · put oi: 2,975
Expected Move to 2026-11-20:
±$32.30
(22.91%) —
implied range
$108.71 –
$173.31
· ATM straddle on $140.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMVT | Immunovant, Inc. | $7.93B | $38.62 | — |
| PCVX | Vaxcyte, Inc. | $7.81B | $54.08 | — |
| APGE | Apogee Therapeutics, Inc. | $8.27B | $134.09 | — |
| IBRX | ImmunityBio, Inc. | $7.51B | $7.17 | — |
| KYMR | Kymera Therapeutics, Inc. | $8.51B | $103.40 | — |
News headlines (Yahoo Finance, 1h cache)
AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
2026-07-31 15:14 · Yahoo
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade
2026-07-30 13:55 · Yahoo
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up
2026-07-29 16:23 · Yahoo
Why Repligen (RGEN) Stock Is Up Today
2026-07-29 08:21 · Yahoo
Repligen (RGEN) Held An M&A Call With BioLife Solutions.
2026-07-28 20:12 · Yahoo
Repligen Corp (RGEN) Q2 2026 Earnings Call Highlights: Strong Growth and Raised Guidance Amidst ...
2026-07-28 19:01 · Yahoo
Repligen Q2 Earnings Call Highlights
2026-07-28 15:04 · Yahoo
Repligen Reports Q2 Revenue Growth and Raises Full-Year 2026 Guidance
2026-07-28 14:05 · Yahoo
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
2026-07-28 12:15 · Yahoo
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026
2026-07-28 11:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.